All In Biotech

Drug Trial Radar · NCT02607891

A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy

Last checked: Nov 19, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Nov 9, 2016

Primary completion

Sep 11, 2018

Study completion Oct 2, 2018

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will be randomized in a 4:1 ratio to receive GWP42003-P or matching placebo. The hypothesis is that levels of stiripentol (STP) or valproate (VPA) may be altered (increased or decreased) as a result of using GWP42003-P.

Conditions

  • Epilepsy

Interventions

  • GWP42003-PDrug

    Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

  • PlaceboDrug

    Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD).Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
  2. Time to the maximum plasma concentration (Tmax) of STP, VPA and CBD.Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
  3. Area under the curve (AUC) from zero to final time of positive detection (0-t) of STP, VPA and CBD.Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.
  4. Area under the plasma concentration time curve over a dosing interval, where tau is the dosing interval [AUCtau].Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • SEIN - Epilepsy Institute in the Netherlands Foundation

    Zwolle, Netherlands

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Ruber Internacional

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.